Literature DB >> 17555408

Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.

Yuanda Song1, Palmer Wilkins, Wenhui Hu, Karnam S Murthy, Jing Chen, Zendra Lee, Regina Oyesanya, Jinhua Wu, Suzanne E Barbour, Xianjun Fang.   

Abstract

PLA2 (phospholipase A2) enzymes play critical roles in membrane phospholipid homoeostasis and in generation of lysophospholipid growth factors. In the present study, we show that the activity of the cytosolic iPLA2 (calcium-independent PLA2), but not that of the calcium-dependent cPLA2 (cytosolic PLA2), is required for growth-factor-independent, autonomous replication of ovarian carcinoma cells. Blocking iPLA2 activity with the pharmacological inhibitor BEL (bromoenol lactone) induces cell cycle arrest in S- and G2/M-phases independently of the status of the p53 tumour suppressor. Inhibition of iPLA2 activity also leads to modest increases in apoptosis of ovarian cancer cells. The S- and G2/M-phase accumulation is accompanied by increased levels of the cell cycle regulators cyclins B and E. Interestingly, the S-phase arrest is released by supplementing the growth factors LPA (lysophosphatidic acid) or EGF (epidermal growth factor). However, inhibition of iPLA2 activity with BEL remains effective in repressing growth-factor- or serum-stimulated proliferation of ovarian cancer cells through G2/M-phase arrest. Down-regulation of iPLA2b expression with lentivirus-mediated RNA interference inhibited cell proliferation in culture and tumorigenicity of ovarian cancer cell lines in nude mice. These results indicate an essential role for iPLA2 in cell cycle progression and tumorigenesis of ovarian carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555408      PMCID: PMC2049037          DOI: 10.1042/BJ20070631

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  39 in total

1.  Pyrrolidine inhibitors of human cytosolic phospholipase A(2).

Authors:  K Seno; T Okuno; K Nishi; Y Murakami; F Watanabe; T Matsuura; M Wada; Y Fujii; M Yamada; T Ogawa; T Okada; H Hashizume; M Kii; S Hara; S Hagishita; S Nakamoto; K Yamada; Y Chikazawa; M Ueno; I Teshirogi; T Ono; M Ohtani
Journal:  J Med Chem       Date:  2000-03-23       Impact factor: 7.446

2.  The effect of high molecular phospholipase A2 inhibitors on 3T6 fibroblast proliferation.

Authors:  T Sanchez; J J Moreno
Journal:  Biochem Pharmacol       Date:  2001-04-01       Impact factor: 5.858

3.  Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2.

Authors:  A M Eder; T Sasagawa; M Mao; J Aoki; G B Mills
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

4.  Caspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in non-apoptotic ovarian cancer cells.

Authors:  Xiaoxian Zhao; Dongmei Wang; Zhenwen Zhao; Yingyi Xiao; Saubhik Sengupta; Yijin Xiao; Renliang Zhang; Kirsten Lauber; Sebastian Wesselborg; Li Feng; Tyler M Rose; Yue Shen; Junjie Zhang; Glenn Prestwich; Yan Xu
Journal:  J Biol Chem       Date:  2006-08-01       Impact factor: 5.157

Review 5.  The Pezcoller lecture: cancer cell cycles revisited.

Authors:  C J Sherr
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

6.  Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

Authors:  Limin Hu; Judith Hofmann; Yiling Lu; Gordon B Mills; Robert B Jaffe
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

Review 7.  Regulation of mammalian cell membrane biosynthesis.

Authors:  A Lykidis; S Jackowski
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

8.  Human calcium-independent phospholipase A2 mediates lymphocyte proliferation.

Authors:  A K Roshak; E A Capper; C Stevenson; C Eichman; L A Marshall
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

Review 9.  The expanding superfamily of phospholipase A(2) enzymes: classification and characterization.

Authors:  D A Six; E A Dennis
Journal:  Biochim Biophys Acta       Date:  2000-10-31

Review 10.  Lysophosphatidic acid is a bioactive mediator in ovarian cancer.

Authors:  Xianjun Fang; Michel Schummer; Muling Mao; Shuangxing Yu; Fazal Haq Tabassam; Ramona Swaby; Yutaka Hasegawa; Janos L Tanyi; Ruthie LaPushin; Astrid Eder; Robert Jaffe; Jim Erickson; Gordon B Mills
Journal:  Biochim Biophys Acta       Date:  2002-05-23
View more
  34 in total

1.  Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development.

Authors:  Hui Li; Zhenwen Zhao; Gang Wei; Libo Yan; Dongmei Wang; Hong Zhang; George Earl Sandusky; John Turk; Yan Xu
Journal:  FASEB J       Date:  2010-06-08       Impact factor: 5.191

Review 2.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.

Authors:  Mu-En Lin; Deron R Herr; Jerold Chun
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-03-04       Impact factor: 3.072

3.  Association of lipid metabolism with ovarian cancer.

Authors:  M Tania; M A Khan; Y Song
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

Review 4.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

5.  Phospholipids of tumor extracellular vesicles stratify gefitinib-resistant nonsmall cell lung cancer cells from gefitinib-sensitive cells.

Authors:  Jae Hun Jung; Min Young Lee; Do-Young Choi; Jae Won Lee; Sungyong You; Kye Young Lee; Jayoung Kim; Kwang Pyo Kim
Journal:  Proteomics       Date:  2015-01-16       Impact factor: 3.984

6.  Extinction of Tumor Antigen Expression by SF2/ASF in JCV-Transformed Cells.

Authors:  Elena Uleri; Sarah Beltrami; Jennifer Gordon; Antonina Dolei; Ilker Kudret Sariyer
Journal:  Genes Cancer       Date:  2011-07

7.  Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development.

Authors:  Hui Li; Zhenwen Zhao; Caryl Antalis; Zhanzhong Zhao; Robert Emerson; Gang Wei; Sheng Zhang; Zhong-Yin Zhang; Yan Xu
Journal:  Am J Pathol       Date:  2011-05-17       Impact factor: 4.307

Review 8.  Group VIA Ca2+-independent phospholipase A2 (iPLA2beta) and its role in beta-cell programmed cell death.

Authors:  Xiaoyong Lei; Suzanne E Barbour; Sasanka Ramanadham
Journal:  Biochimie       Date:  2010-01-18       Impact factor: 4.079

9.  H2O2-dependent hyperoxidation of peroxiredoxin 6 (Prdx6) plays a role in cellular toxicity via up-regulation of iPLA2 activity.

Authors:  So Yong Kim; Hee-Yeon Jo; Mi Hye Kim; Yun-yi Cha; Sung Won Choi; Jae-Hyuck Shim; Tae Jin Kim; Ki-Young Lee
Journal:  J Biol Chem       Date:  2008-09-30       Impact factor: 5.157

10.  Smooth muscle cell arachidonic acid release, migration, and proliferation are markedly attenuated in mice null for calcium-independent phospholipase A2beta.

Authors:  Sung Ho Moon; Christopher M Jenkins; David J Mancuso; John Turk; Richard W Gross
Journal:  J Biol Chem       Date:  2008-10-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.